A MULTI-CENTER, RANDOMIZED, BLINDED STUDY COMPARING THE EFFECT OF CRx-150 PLUS DMARD THERAPY TO THAT OF PLACEBO PLUS DMARD THERAPY ON SERUM C-REACTIVE PROTEIN (CRP) AND CYTOKINES IN SUBJECTS WITH RHEUMATOID ARTHRITIS

Trial Profile

A MULTI-CENTER, RANDOMIZED, BLINDED STUDY COMPARING THE EFFECT OF CRx-150 PLUS DMARD THERAPY TO THAT OF PLACEBO PLUS DMARD THERAPY ON SERUM C-REACTIVE PROTEIN (CRP) AND CYTOKINES IN SUBJECTS WITH RHEUMATOID ARTHRITIS

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2011

At a glance

  • Drugs Amoxapine/dipyridamole (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms CRx150RA
  • Sponsors Zalicus
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jun 2011 New source identified and integrated (European Clinical Trials Database)
    • 29 Jun 2007 According to CombinatoRx media release, product candidate CRx-150 [amoxapine/dipyridamole] shows activity on DAS28 and Pain, but Not CRP, failing to meet target product profile.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top